{
  "symbol": "BIIB",
  "year": 2022,
  "period": "Q3",
  "curated_text": "Symbol: BIIB. Year: 2022. Period: Q3. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: COVID-19, Solothurn, 3 Table of Contents \u2022, Biogen Inc., MabThera, PLEGRIDY\u00ae, TYSABRI\u00ae, Biogen, BENEPALI, FLIXABI, FUMADERM, IMRALDI, ENBREL\u00ae, FAMPYRA, 753.9 478.1 Research, Diluted, Contents BIOGEN INC., EQUITY, Taxes, Treasury, 7 Table of Contents BIOGEN INC., Retained, Total Biogen Inc., 9 Table of Contents BIOGEN INC., 125.4 Capital, Share Repurchase Program, CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, Business Overview Biogen, SMA, TECFIDERA, VUMERITY, AVONEX, TYSABRI, non-Hodgkin's, CLL, Genentech, Inc., Genentech, the Roche Group, Samsung Bioepis Co., Ltd., ENBREL, HUMIRA, BYOOVIZ, the European Union, Consolidated Financial Statements, the Financial Accounting Standards Board, Cost Saving Initiatives, Fumarate, Interferon, the U.S. Food and Drug Administration, FDA, Samsung, Medicare, Medicaid Services, CMS, National Coverage Decision (NCD, NCD, Eisai, GOODWILL Intangible Assets Intangible, TGN, Completed Technology Completed, Business Combinations, Convergence Pharmaceuticals Holdings Ltd., DPN, ac, Sangamo Therapeutics, Inc., Sangamo, Sage Therapeutics, Inc., Denali Therapeutics Inc., Denali, Financial Instruments, Fair Value Valuation Technique Unobservable Input(s, Level, Fair Value Carrying Value Fair Value Carrying Value, Indebtedness, Biogen International Neuroscience GmbH, 454.8 Government, Current 878.7 1.0, 384.8 Government, Marketable Debt Securities, Denali, Ionis Pharmaceuticals, Inc., AOCI, 59.9 Total, Net Investment Hedges - Hedging Instruments, Samsung BioLogics, Foreign Currency Forward Contracts - Other Derivative Instruments We, 66.2 Investments, PLANT AND EQUIPMENT Property, Switzerland Manufacturing Facility, Good Manufacturing Practice, the Swiss Agency for Therapeutic Products, the Prior Approval Supplement, INDEBTEDNESS Exchange, 24 Table of Contents BIOGEN INC., EQUITY Share Repurchases, Board of Directors, Cash Flow Hedges, Net Investment Hedge, Net of Tax Currency Translation Adjustments Total Balance, SHARE-BASED, Neurimmune SubOne, AG, Tax Basis, The U.S. Internal Revenue Service, CONSOLIDATED FINANCIAL STATEMENT DETAIL, Net Components, Liabilities, RELATIONSHIPS Eisai Co., Eisai Co., Ltd., the Lecanemab Collaboration, lecanemab development, The Lecanemab Collaboration, the ADUHELM Collaboration Agreement, PLEGRIDY, UCB, the U.S. Outside, LRRK2, Denali\u2019s Transport, Antibody Transport Vehicle, ATV, Transport Vehicle, InnoCare Pharma Limited, InnoCare, Bruton, Development and Commercialization Agreement, Samsung 33 Table of Contents BIOGEN INC., Bioepis, Unconsolidated Variable Interest, the U.S., District Court, U.S.C, the Board of Directors, C.F.R., IMRALDI Patent Litigation, Fresenius Kabi Deutschland GmbH, Biogen France SAS, the Tribunal de Grande Instance de Paris, Biogen GmbH, the D\u00fcsseldorf Regional Court, the European Patent Office, EPO, Technical Boards of Appeal, Fresenius Kabi, Maritime, Commercial High Court, Court, the High Court, the Danish Patent Board of Appeal, the U.S. District Court, Shareholder Representative Services LLC, ERISA, Humana Patient Assistance Litigation, Humana Inc., Humana, The U.S. House of Representatives Committees, the Office of Inspector General, the U.S. Department of Health and Human Services, Company, the Federal Trade Commission, the Securities and Exchange Commission, TECFIDERA Patent Matters, TECFIDERA Orange-Book, the Drug Price Competition and Patent Term Restoration Act, the Hatch-Waxman Act, the Delaware Actions, Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Zydus Pharmaceuticals, the Delaware Defendants, the Delaware Court, Mylan, the West Virginia Action, the West Virginia Court, the Federal Circuit, The Delaware Court, Mylan Pharmaceuticals, Inc., the U.S. Patent Trial and Appeal Board, the United States Supreme Court, TYSABRI Patent Revocation Matters, Swiss Pharma International AG, the Polpharma Group, the Commercial Court of Rome, the European Patent No, Polpharma Biologics S.A., the Polish Patent Office, Sandoz B.V., Sandoz AG, the District Court, EPO\u2019s Technical Boards of Appeal, Sandoz Limited, Annulment Proceedings, General Court, TECFIDERA Pharmaceutical Works Polpharma SA, Mylan Ireland Ltd., the General Court, the European Union (, the European Medicines Agency's, EMA, the European General Court, the European Court of Justice, the Board of Directors of Biogen, MANAGEMENT'S, ANALYSIS OF FINANCIAL CONDITION, GMP. Context excerpt: competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candi",
  "competition_summary": [
    {
      "competitor": "COVID-19",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Solothurn",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "3 Table of Contents \u2022",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen Inc.",
      "mentions": 16,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MabThera",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PLEGRIDY\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TYSABRI\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen",
      "mentions": 17,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BENEPALI",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FLIXABI",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FUMADERM",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IMRALDI",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ENBREL\u00ae",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FAMPYRA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "753.9 478.1 Research",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Diluted",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Contents BIOGEN INC.",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EQUITY",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Taxes",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Treasury",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "7 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Retained",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Total Biogen Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "9 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "125.4 Capital",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Share Repurchase Program",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
      "mentions": 29,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Business Overview Biogen",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SMA",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TECFIDERA",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "VUMERITY",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AVONEX",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TYSABRI",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "non-Hodgkin's",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CLL",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Genentech, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Genentech",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Roche Group",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung Bioepis Co., Ltd.",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ENBREL",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "HUMIRA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "BYOOVIZ",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Union",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Consolidated Financial Statements",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Financial Accounting Standards Board",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Cost Saving Initiatives",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Fumarate",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Interferon",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Food and Drug Administration",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "FDA",
      "mentions": 6,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Medicare",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Medicaid Services",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CMS",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "National Coverage Decision (NCD",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "NCD",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai",
      "mentions": 23,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "GOODWILL Intangible Assets Intangible",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TGN",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Completed Technology Completed",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Business Combinations",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Convergence Pharmaceuticals Holdings Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "DPN",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ac",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sangamo Therapeutics, Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sangamo",
      "mentions": 8,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sage Therapeutics, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali Therapeutics Inc.",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Financial Instruments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Fair Value Valuation Technique Unobservable Input(s",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Level",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Fair Value Carrying Value Fair Value Carrying Value",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Indebtedness",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen International Neuroscience GmbH",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "454.8 Government",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Current 878.7 1.0",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "384.8 Government",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Marketable Debt Securities",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali, Ionis Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AOCI",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "59.9 Total",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Net Investment Hedges - Hedging Instruments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung BioLogics",
      "mentions": 4,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Foreign Currency Forward Contracts - Other Derivative Instruments We",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "66.2 Investments",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PLANT AND EQUIPMENT Property",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Switzerland Manufacturing Facility",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Good Manufacturing Practice",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Swiss Agency for Therapeutic Products",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Prior Approval Supplement",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "INDEBTEDNESS Exchange",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "24 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EQUITY Share Repurchases",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Board of Directors",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Cash Flow Hedges",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Net Investment Hedge",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Net of Tax Currency Translation Adjustments Total Balance",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "SHARE-BASED",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Neurimmune SubOne",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "AG",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Tax Basis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "The U.S. Internal Revenue Service",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "CONSOLIDATED FINANCIAL STATEMENT DETAIL",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Net Components",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Liabilities",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "RELATIONSHIPS Eisai Co.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Eisai Co., Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Lecanemab Collaboration",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "lecanemab development",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "The Lecanemab Collaboration",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the ADUHELM Collaboration Agreement",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "PLEGRIDY",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "UCB",
      "mentions": 7,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Outside",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "LRRK2",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Denali\u2019s Transport",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Antibody Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ATV",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Transport Vehicle",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "InnoCare Pharma Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "InnoCare",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bruton",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Development and Commercialization Agreement",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Samsung 33 Table of Contents BIOGEN INC.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Bioepis",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Unconsolidated Variable Interest",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S.",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "District Court",
      "mentions": 5,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "U.S.C",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Board of Directors",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "C.F.R.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "IMRALDI Patent Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Fresenius Kabi Deutschland GmbH",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen France SAS",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Tribunal de Grande Instance de Paris",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Biogen GmbH",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the D\u00fcsseldorf Regional Court",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Patent Office",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EPO",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Technical Boards of Appeal",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Fresenius Kabi",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Maritime",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Commercial High Court",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the High Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Danish Patent Board of Appeal",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Shareholder Representative Services LLC",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ERISA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Humana Patient Assistance Litigation",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Humana Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Humana",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "The U.S. House of Representatives Committees",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Office of Inspector General",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Department of Health and Human Services",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Company",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Federal Trade Commission",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Securities and Exchange Commission",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TECFIDERA Patent Matters",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TECFIDERA Orange-Book",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Drug Price Competition and Patent Term Restoration Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Hatch-Waxman Act",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Delaware Actions",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Accord Healthcare Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Alkem Laboratories Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Amneal Pharmaceuticals LLC",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Cipla Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Graviti Pharmaceuticals Pvt. Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Hetero USA, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Lupin Atlantis Holdings SA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Macleods Pharmaceuticals, Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MSN Laboratories Pvt. Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Pharmathen S.A.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Prinston Pharmaceutical Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Shilpa Medicare Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sun Pharmaceutical Industries, Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sun Pharmaceutical Industries, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sun Pharma Global FZE",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Torrent Pharmaceuticals Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TWi Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Windlas Healthcare Pvt. Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Zydus Pharmaceuticals",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Delaware Defendants",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Delaware Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Mylan",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the West Virginia Action",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the West Virginia Court",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Federal Circuit",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "The Delaware Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Mylan Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the U.S. Patent Trial and Appeal Board",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the United States Supreme Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TYSABRI Patent Revocation Matters",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Swiss Pharma International AG",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Polpharma Group",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Commercial Court of Rome",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Patent No",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Polpharma Biologics S.A.",
      "mentions": 3,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Polish Patent Office",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sandoz B.V.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sandoz AG",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the District Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EPO\u2019s Technical Boards of Appeal",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Sandoz Limited",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Annulment Proceedings",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "General Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "TECFIDERA Pharmaceutical Works Polpharma SA",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "Mylan Ireland Ltd.",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the General Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Union (",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Medicines Agency's",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "EMA",
      "mentions": 2,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European General Court",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the European Court of Justice",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "the Board of Directors of Biogen",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "MANAGEMENT'S",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    },
    {
      "competitor": "GMP",
      "mentions": 1,
      "context": "competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate "
    }
  ]
}